Medscape Conference Coverage, based on selected sessions at the:

Heart Failure Society of America (HFSA) 11th Annual Scientific Meeting

September 16 - 19, 2007; Washington, DC

This activity is not sanctioned by, nor a part of, the Heart Failure Society of America.

Conference News

  • BNP Test Helps Predict Anthracycline Cardiotoxicity

    Measuring BNP at each treatment course can help clinicians know when to withdraw the drugs, according to investigators.
  • Home Telemonitoring for HF in Primary-Care Setting

    A device that streamlines the reporting of weight and symptom changes seemed to add little to outpatient heart-failure management by primary-care physicians, conclude researchers from a study that also enrolled predominantly women and minorities.
  • DAVID-2: No Quality-of-Life Differences Between AAI-70 and VVI-40

    That is, in low-LVEF patients with ICDs but no conventional pacing indication, the trial suggests, which had also seen similar clinical outcomes with the two pacing modes.
  • ECLIPSE Sheds Light on Tolvaptan Mechanistic Effects

    The investigational vasopressin antagonist's clinical effects and safety profile are well characterized; now more is known about its hemodynamic effects.
  • Reimbursement Catch-Up With HF Disease Management Programs

    A lot of substantive care within cash-strapped heart-failure disease management programs happens over the telephone. It takes time--time that current reimbursement schedules overlook, according to researchers.
  • Outpatient HF Quality of Care Varies Widely in Analysis

    Some practices have been great at applying management guidelines to patients with chronic heart failure; others have their work cut out for them, sometimes in surprisingly fundamental ways, according to early findings from the IMPROVE-HF performance-improvement initiative.

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the Heart Failure Society of America. These materials and the related activity are not sanctioned by the Heart Failure Society of America or the commercial supporter of the conference and do not constitute an official part of that conference.